These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 32821149)

  • 1. Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence.
    Gower MN; Ratner LR; Williams AK; Rossi JS; Stouffer GA; Lee CR
    Pharmgenomics Pers Med; 2020; 13():239-252. PubMed ID: 32821149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
    Klein MD; Williams AK; Lee CR; Stouffer GA
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of P2Y
    Thomas CD; Williams AK; Lee CR; Cavallari LH
    Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes and Sustainability of Using
    Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
    Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
    Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y
    Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
    Klein MD; Lee CR; Stouffer GA
    Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of race and ethnicity disparities in outcome studies of
    Nguyen AB; Cavallari LH; Rossi JS; Stouffer GA; Lee CR
    Front Cardiovasc Med; 2022; 9():991646. PubMed ID: 36082121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory.
    Gurbel PA; Bliden K; Sherwood M; Taheri H; Tehrani B; Akbari M; Yazdani S; Asgar JA; Chaudhary R; Tantry US
    J Thromb Thrombolysis; 2024 Apr; 57(4):566-575. PubMed ID: 38480590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
    Martin J; Williams AK; Klein MD; Sriramoju VB; Madan S; Rossi JS; Clarke M; Cicci JD; Cavallari LH; Weck KE; Stouffer GA; Lee CR
    Genet Med; 2020 Jan; 22(1):160-169. PubMed ID: 31316169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
    Cavallari LH
    Expert Rev Cardiovasc Ther; 2017 Aug; 15(8):581-589. PubMed ID: 28699807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y
    Cavallari LH; Limdi NA; Beitelshees AL; Lee JC; Duarte JD; Franchi F; Tuteja S; Giri J; Empey PE; Kreutz RP; Skaar TC; Allen JM; Coons JC; Gong Y; McDonough CW; Stevenson JM; Thomas CD; Johnson JA; Stouffer GA; Angiolillo DJ; Lee CR;
    Clin Pharmacol Ther; 2023 Mar; 113(3):615-623. PubMed ID: 36306392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al-Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Loza BL; Claassens DMF; Asselbergs FW; Al-Ali AK
    Int J Cardiol; 2021 Nov; 343():15-20. PubMed ID: 34506827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.